ライフサイエンスコーパス: nontreated group

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 and 73 (65%) received no additional therapy (nontreated group).

2 ssed ROP who had not received any treatment (nontreated group).

3 ficantly lower incidence of infection in the nontreated group.

4 in the treated group and 17.8 months in the nontreated group.

5 and GC were markedly lower compared with the nontreated group.

6 d animals viral load was 2.58 +/- 1.0 in the nontreated group, 4.74 +/- 1.38 in the group treated wit

7 choroidal thickness than the patients in the nontreated group after adjusting for age, axial length,

8 ues during the endotoxic phase (P < 0.05 vs. nontreated group, ANOVA).

9 O2 (140% and 79%, respectively; P < 0.05 vs. nontreated group, ANOVA).

10 remained within baseline range (P < 0.05 vs. nontreated group, ANOVA).

11 The nontreated group exhibited persistent endogenous glucose

12 used to achieve comparability of treated and nontreated groups in terms of their observed covariates

13 come versus 255 of 422 patients (63%) in the nontreated group (p < 0.001).

14 wer subbasal nerves number compared with the nontreated group (P = 0.01).

15 roup and 0.032 episodes/patient-month in the nontreated group (p = 0.04).

16 roup and 0.012 episodes/patient-month in the nontreated group (p = 0.05).

17 roup and 0.035 episodes/patient-month in the nontreated group (p = 0.56).

18 roup and 0.029 episodes/patient-month in the nontreated group (p = 0.64).

19 group and 67% and 41 %, respectively, in the nontreated group (p = 0.77).

20 mol/mL and < 6.0 mumol/mL in the treated and nontreated groups, respectively) and reduced tPA levels

21 genation group, whereas the sham-treated and nontreated groups showed retinal thinning and choroidal

22 NV in the ribavirin-treated (100 microM) and nontreated groups showed that the mutation rates were si

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。